Immunotherapy of Renal and Bladder Cancers

15.

Lamm DL, Bluemenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.PubMed

16.

Shelley MD, Court J, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guerin in 154, Ta and Tl bladder cancer. Cochrane Database Syst Rev. 2000;(4):CD001986.

17.

Lamm D. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Huntingt). 1995;9:947–52.

18.

Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette–Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205–9.PubMed

19.

Herr HW, Schwalb DM, Zhang Z-F, Sogani PC, Fair WR, Whitmore W, et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13(6):1404–8.PubMed

20.

Lamm D. Optimal BCG, treatment of superficial bladder cancer as defined by American trials. Eur Urol. 1991;21:12–6.

21.

Bassi P, Spinadin R, Carando R, Balta G, Pagano F. Modified induction course: a solution to side-effects? Eur Urol. 2000;37 Suppl 1:31–2.PubMed

22.

Cheng C, Ng M, Chan S, Sun W. Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review. ANZ J Surg. 2004;74(7):569–72.PubMed

23.

Lamm DL, Reichert D, Harris S, Lucio R. Immunotherapy of murine transitional cell carcinoma. J Urol. 1982;128(5):1104–8.PubMed

24.

Alexandroff AB, Jackson AM, O’Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353(9165):1689–94.PubMed

25.

Rubenstein M, Muchnik S, Chet M, Shaw M, McKiel C, Guinan P. Tumor infiltrating lymphocytes: the effect of bacillus Calmette Guerin on helper/suppressor-T cell ratios of treated and untreated tumors. J Urol. 1991;146(6):1650–3.PubMed

26.

Shemtov MM, Cheng DL-W, Kong L, Shu W-P, Sassaroli M, Droller MJ, et al. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy. J Urol. 1995;154(1):269–74.PubMed

27.

Jackson AM, Alexandroff A, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD, James K. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol. 1995;99(99):369–75.PubMedCentralPubMed

28.

Yamada H, Luo Y, Matsumoto T, O’DONNELL MA. A novel expression of macrophage derived chemokine in human bladder cancer. J Urol. 2005;173(3):990–5.PubMed

29.

Bevers R, De Boer E, Kurth K, Schamhart D. BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Net. 1998;9(2):181–6.

30.

Gan Y-H, Mahendran R, James K, Lawrencia C, Esuvaranathan K. Evaluation of lymphocytic responses after treatment with bacillus Calmette-Guerin and interferon-α 2b for superficial bladder cancer. Clin Immunol. 1999;90(2):230–7.PubMed

31.

Sargent E, Williams R. Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin. Urol Clin N Am. 1992;19(3):581–9.

32.

Glashan R. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol. 1990;144(3):658–61.PubMed

33.

Zhang Y, Khoo HE, Esuvaranathan K. Effects of bacillus Calmette-Guerin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol. 1999;161(3):977–83.PubMed

34.

Smit JJFG, Nijkamp FP. Ramp-ing up allergies: Nramp1 (Slc11a1), macrophages and the hygiene hypothesis. Trends Immunol. 2004;25:342–7.

35.

Hara I, Sato N, Miyake H, Muramaki M, Hikosaka S, Kamidono S. Introduction of 65 kDa antigen of mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy. Microbiol Immunol. 2004;48(4):289–95.PubMed

36.

Reale M, Intorno R, Tenaglia R, Feliciani C, Barbacane RC, Santoni A, et al. Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol Immunother. 2002;51(2):91–8.PubMed

37.

Hudson M, Brown E, Ritchey J, Ratliff T. Modulation of fibronectin-mediated Bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res. 1991;51(14):3726–32.PubMed

38.

Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest. 1990;85(1):62.PubMedCentralPubMed

39.

Lang T, Prina E, Sibthorpe D, Blackwell JM. Nramp1 transfection transfers Ity/Lsh/Bcg-related pleiotropic effects on macrophage activation: influence on antigen processing and presentation. Infect Immun. 1997;65(2):380–6.PubMedCentralPubMed

40.

Smith Jr JA, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). J Urol. 1999;162(5):1697–701.PubMed

41.

Gruenheid S, Pinner E, Desjardins M, Gros P. Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. J Exp Med. 1997;185(4):717–30.PubMedCentralPubMed

42.

Arias M, Rojas M, Zabaleta J, Rodríguez JI, París SC, Barrera LF, et al. Inhibition of virulent Mycobacterium tuberculosis by Bcgr and Bcgs macrophages correlates with nitric oxide production. J Infect Dis. 1997;176(6):1552–8.PubMed

43.

Kadhim SA, Chin JL, Batislam E, Karlik SJ, Garcia B, Skamene E. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor. J Urol. 1997;158(2):646–52.PubMed

44.

Chopin D, PJJ, Saint F, Bari R, Velotti F, Abbou C. Bases et principes de l’immunothérapie locale utilisant le bacille Calmette Guérin dans le carcinome urothélial vésicale. Implications pratiques. Prog Urol. 1998;8(Suppl 2):8–12.

45.

Sousa AO, Lee FK, Freiji R, Lagrange PH, André N. Human immunodeficiency virus infection alters antigen-induced cytokine responses in patients with active mycobacterial diseases. J Infect Dis. 1998;177(6):1554–62.PubMed

46.

Becich M, Carroll S, Ratliff T. Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol. 1991;145(6):1316–24.PubMed

47.

Fleischmann J, Park M-C, Hassan M. Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy. J Urol. 1993;149(2):268–71.PubMed

48.

Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res. 1992;52(15):4286–90.PubMed

49.

Böhle A, Nowc C, Ulmer A, Musehold J, Gerdes J, Hofstetter A, et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol. 1990;144(1):59–64.PubMed

50.

De Boer E, De Jong W, Steerenberg P, Aarden L, Tetteroo E, De Groot E, et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother. 1992;34(5):306–12.PubMed

Only gold members can continue reading. Log In or Register to continue